News for PULM Stock

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets Pulmatrix and Cullgen Announce Proposed Merger Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update Pulmatrix Supports World Asthma Day 2023 Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD Pulmatrix Regains Compliance With Nasdaq Listing Requirements Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split Pulmatrix Issues Letter to Stockholders Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering Pulmatrix Announces $6.75 Million Registered Direct Offering Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmatrix Announces Resolution of Contract Dispute with Cipla Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update Pulmatrix appoints Director Anand Varadan Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Pulmatrix Reports 2020 Financial Results and Provides Business Update Pulmatrix Provides a Pipeline and Business Update Pulmatrix Announces Closing of $40 Million Registered Direct Offering Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore Pulmatrix Reports Progress on Product Pipeline Pulmatrix Reports Q2 2020 Results and Business Updates